GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » Current Ratio

Curative Biotechnology (Curative Biotechnology) Current Ratio : 0.02 (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Curative Biotechnology's current ratio for the quarter that ended in Mar. 2023 was 0.02.

Curative Biotechnology has a current ratio of 0.02. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Curative Biotechnology has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Curative Biotechnology's Current Ratio or its related term are showing as below:

CUBT's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.775
* Ranked among companies with meaningful Current Ratio only.

Curative Biotechnology Current Ratio Historical Data

The historical data trend for Curative Biotechnology's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curative Biotechnology Current Ratio Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial - - 3.20 1.03 0.02

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.10 0.01 0.02 0.02

Competitive Comparison of Curative Biotechnology's Current Ratio

For the Biotechnology subindustry, Curative Biotechnology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curative Biotechnology's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's Current Ratio distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's Current Ratio falls into.



Curative Biotechnology Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Curative Biotechnology's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=0.069/4.487
=0.02

Curative Biotechnology's Current Ratio for the quarter that ended in Mar. 2023 is calculated as

Current Ratio (Q: Mar. 2023 )=Total Current Assets (Q: Mar. 2023 )/Total Current Liabilities (Q: Mar. 2023 )
=0.108/5.332
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curative Biotechnology  (OTCPK:CUBT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Curative Biotechnology Current Ratio Related Terms

Thank you for viewing the detailed overview of Curative Biotechnology's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Curative Biotechnology (Curative Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.

Curative Biotechnology (Curative Biotechnology) Headlines

From GuruFocus

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

By GuruFocusNews GuruFocusNews 06-11-2022

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

By GuruFocusNews GuruFocusNews 07-01-2022